N Ameli, D Babazadeh, B Seifdavati, S G Sangar, M M Babayi, D Soltani, A Omranzadeh, F Navoshki
{"title":"利用重要的兽医病原体曲霉真菌治疗肺癌:一种新方法。","authors":"N Ameli, D Babazadeh, B Seifdavati, S G Sangar, M M Babayi, D Soltani, A Omranzadeh, F Navoshki","doi":"10.32592/ARI.2025.80.1.1","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is a persistent global health problem that necessitates innovative therapeutic approaches for effective intervention. In recent years, there has been a significant increase in research focusing on the potential anti-cancer properties of various filamentous Aspergillus molds. This review aims to systematically assess the scientific evidence regarding the potential anti-tumor effects of distinct Aspergillus species and their secondary metabolites in the context of lung cancer. A multitude of Aspergillus species, with Aspergillus fumigatus being a prominent example, have exhibited the capacity to generate compounds that hold considerable promise in the realm of anti-cancer therapeutics. Gliotoxin, a notable example, has been identified as a crucial agent inducing apoptosis in lung cancer cells while impeding tumor growth. Furthermore, Emericellamide A, a secondary metabolite derived from Aspergillus nidulans, exhibits significant toxicity against lung cancer cells. Serotonin, a natural product of Aspergillus terreus, has also been shown to have significant cytotoxic effects on lung cancer cells. Cycloopiazonic acid, a natural product of Aspergillus flavus, has exhibited significant anti-lung cancer properties, thus augmenting the existing repertoire of potential anti-cancer agents. The inhibitory effects on cancer cells extend beyond mere toxicity, involving processes such as apoptosis, regulation of angiogenesis, immune modulation, and suppression of proliferation. Despite the encouraging array of anti-cancer compounds presented by Aspergillus fungi, significant challenges persist in their identification, scalable production, and understanding of their interactions with existing therapeutic modalities. Addressing these challenges necessitates collaborative efforts, fostering synergy among researchers, clinicians, and industry stakeholders. Research into the pharmacological repertoire offered by Aspergillus fungi can only be successful with the concerted efforts of researchers to determine the best possible treatment options for lung cancer, leveraging the wide variety of therapeutic options available.</p>","PeriodicalId":8311,"journal":{"name":"Archives of Razi Institute","volume":"80 1","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426429/pdf/","citationCount":"0","resultStr":"{\"title\":\"Utilizing <i>Aspergillus Fungi</i>, a Significant Veterinary Pathogen, in Lung Cancer Treatment: A Novel Approach.\",\"authors\":\"N Ameli, D Babazadeh, B Seifdavati, S G Sangar, M M Babayi, D Soltani, A Omranzadeh, F Navoshki\",\"doi\":\"10.32592/ARI.2025.80.1.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer is a persistent global health problem that necessitates innovative therapeutic approaches for effective intervention. In recent years, there has been a significant increase in research focusing on the potential anti-cancer properties of various filamentous Aspergillus molds. This review aims to systematically assess the scientific evidence regarding the potential anti-tumor effects of distinct Aspergillus species and their secondary metabolites in the context of lung cancer. A multitude of Aspergillus species, with Aspergillus fumigatus being a prominent example, have exhibited the capacity to generate compounds that hold considerable promise in the realm of anti-cancer therapeutics. Gliotoxin, a notable example, has been identified as a crucial agent inducing apoptosis in lung cancer cells while impeding tumor growth. Furthermore, Emericellamide A, a secondary metabolite derived from Aspergillus nidulans, exhibits significant toxicity against lung cancer cells. Serotonin, a natural product of Aspergillus terreus, has also been shown to have significant cytotoxic effects on lung cancer cells. Cycloopiazonic acid, a natural product of Aspergillus flavus, has exhibited significant anti-lung cancer properties, thus augmenting the existing repertoire of potential anti-cancer agents. The inhibitory effects on cancer cells extend beyond mere toxicity, involving processes such as apoptosis, regulation of angiogenesis, immune modulation, and suppression of proliferation. Despite the encouraging array of anti-cancer compounds presented by Aspergillus fungi, significant challenges persist in their identification, scalable production, and understanding of their interactions with existing therapeutic modalities. Addressing these challenges necessitates collaborative efforts, fostering synergy among researchers, clinicians, and industry stakeholders. Research into the pharmacological repertoire offered by Aspergillus fungi can only be successful with the concerted efforts of researchers to determine the best possible treatment options for lung cancer, leveraging the wide variety of therapeutic options available.</p>\",\"PeriodicalId\":8311,\"journal\":{\"name\":\"Archives of Razi Institute\",\"volume\":\"80 1\",\"pages\":\"1-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426429/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Razi Institute\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32592/ARI.2025.80.1.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Veterinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Razi Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32592/ARI.2025.80.1.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Veterinary","Score":null,"Total":0}
Utilizing Aspergillus Fungi, a Significant Veterinary Pathogen, in Lung Cancer Treatment: A Novel Approach.
Cancer is a persistent global health problem that necessitates innovative therapeutic approaches for effective intervention. In recent years, there has been a significant increase in research focusing on the potential anti-cancer properties of various filamentous Aspergillus molds. This review aims to systematically assess the scientific evidence regarding the potential anti-tumor effects of distinct Aspergillus species and their secondary metabolites in the context of lung cancer. A multitude of Aspergillus species, with Aspergillus fumigatus being a prominent example, have exhibited the capacity to generate compounds that hold considerable promise in the realm of anti-cancer therapeutics. Gliotoxin, a notable example, has been identified as a crucial agent inducing apoptosis in lung cancer cells while impeding tumor growth. Furthermore, Emericellamide A, a secondary metabolite derived from Aspergillus nidulans, exhibits significant toxicity against lung cancer cells. Serotonin, a natural product of Aspergillus terreus, has also been shown to have significant cytotoxic effects on lung cancer cells. Cycloopiazonic acid, a natural product of Aspergillus flavus, has exhibited significant anti-lung cancer properties, thus augmenting the existing repertoire of potential anti-cancer agents. The inhibitory effects on cancer cells extend beyond mere toxicity, involving processes such as apoptosis, regulation of angiogenesis, immune modulation, and suppression of proliferation. Despite the encouraging array of anti-cancer compounds presented by Aspergillus fungi, significant challenges persist in their identification, scalable production, and understanding of their interactions with existing therapeutic modalities. Addressing these challenges necessitates collaborative efforts, fostering synergy among researchers, clinicians, and industry stakeholders. Research into the pharmacological repertoire offered by Aspergillus fungi can only be successful with the concerted efforts of researchers to determine the best possible treatment options for lung cancer, leveraging the wide variety of therapeutic options available.